Literature DB >> 2514231

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

S D Gillies1, K M Lo, J Wesolowski.   

Abstract

A rapid and generally applicable method for the modification of immunoglobulin cDNAs was developed so that the variable (V) regions could be expressed as cassettes, together with a variety of constant regions. Murine cDNAs were isolated, sequenced and the V regions joined to short oligonucleotides providing both splice donor sites and unique restriction sites for insertion into an expression vector. Using this strategy we have expressed the V regions of several murine antibodies, together with the human gamma 1 constant region. Although most of these chimeric antibodies were readily expressed, one murine light-chain cDNA sequence could not be expressed in transfected hybridoma cells. Reconstruction experiments indicate that the sequence created by the fusion of the murine leader and variable region blocked expression at the level of RNA accumulation. The methods described, as well as the potential problems of expression, are applicable to both traditional cDNA fragments and those obtained by in vitro amplification techniques.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514231     DOI: 10.1016/0022-1759(89)90093-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  46 in total

1.  Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; William J McBride; Robert M Sharkey; Chien-Hsing Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 3.  Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.

Authors:  Zahra Rashidijahanabad; Xuefei Huang
Journal:  Semin Immunol       Date:  2020-01-22       Impact factor: 11.130

Review 4.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

5.  Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.

Authors:  Jason L J Dearling; Stephan D Voss; Patricia Dunning; Erin Snay; Frederic Fahey; Suzanne V Smith; James S Huston; Claude F Meares; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

6.  T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.

Authors:  U Holzer; T Orlikowsky; C Zehrer; W Bethge; M Dohlsten; T Kalland; D Niethammer; G E Dannecker
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

7.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Authors:  M Naramura; S D Gillies; J Mendelsohn; R A Reisfeld; B M Mueller
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

9.  Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates.

Authors:  Stephan D Voss; Suzanne V Smith; Nadine DiBartolo; Lacey J McIntosh; Erika M Cyr; Ali A Bonab; Jason L J Dearling; Edward A Carter; Alan J Fischman; S Ted Treves; Stephen D Gillies; Alan M Sargeson; James S Huston; Alan B Packard
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

10.  Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Authors:  Andrew L Gilman; M Fevzi Ozkaynak; Katherine K Matthay; Mark Krailo; Alice L Yu; Jacek Gan; Adam Sternberg; Jacquelyn A Hank; Robert Seeger; Gregory H Reaman; Paul M Sondel
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.